Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05883644 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05883644 · ClinicalTrials.gov record · last posted 2026-04-30

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Study acronym: SIERRA
StatusActive, Not Recruiting
PhasePhase 3
Started2023-06-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.

Amendment record 26 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 26 times since 2023-05-22; most recent amendment 2026-04-29. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-04-18
Status change Recruiting→Active, Not Recruitingv21
2023-07-10
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05883644
Lead Sponsor AstraZeneca
Conditions Advanced Hepatocellular Carcinoma
Enrollment 111 participants
Start Date 2023-06-27
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-30